175 related articles for article (PubMed ID: 28657062)
1. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol.
Elmholdt TR; Jørgensen B; Ramsing M; Pedersen M; Olesen AB
NDT Plus; 2010 Jun; 3(3):285-287. PubMed ID: 28657062
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol C; Hiremath S
Can Assoc Radiol J; 2018 May; 69(2):136-150. PubMed ID: 29706252
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol CB; Hiremath S
Can J Kidney Health Dis; 2018; 5():2054358118778573. PubMed ID: 29977584
[TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
5. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
6. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease.
Bennett CL; Qureshi ZP; Sartor AO; Norris LB; Murday A; Xirasagar S; Thomsen HS
Clin Kidney J; 2012 Feb; 5(1):82-88. PubMed ID: 22833806
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.
Attari H; Cao Y; Elmholdt TR; Zhao Y; Prince MR
Radiology; 2019 Aug; 292(2):376-386. PubMed ID: 31264946
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium Presence in the Brain After Administration of the Liver-Specific Gadolinium-Based Contrast Agent Gadoxetate: A Systematic Comparison to Multipurpose Agents in Rats.
Jost G; Frenzel T; Boyken J; Schoeckel L; Pietsch H
Invest Radiol; 2019 Aug; 54(8):468-474. PubMed ID: 30932931
[TBL] [Abstract][Full Text] [Related]
10. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
11. Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.
Scott LJ
Clin Drug Investig; 2013 Apr; 33(4):303-14. PubMed ID: 23435930
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
Piersson AD; Gorleku PN
Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis.
Agarwal R; Brunelli SM; Williams K; Mitchell MD; Feldman HI; Umscheid CA
Nephrol Dial Transplant; 2009 Mar; 24(3):856-63. PubMed ID: 18952698
[TBL] [Abstract][Full Text] [Related]
14. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.
Schieda N; Maralani PJ; Hurrell C; Tsampalieros AK; Hiremath S
Can Assoc Radiol J; 2019 Aug; 70(3):226-232. PubMed ID: 31255393
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
Rydahl C; Thomsen HS; Marckmann P
Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
[TBL] [Abstract][Full Text] [Related]
16. 10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.
Endrikat J; Dohanish S; Schleyer N; Schwenke S; Agarwal S; Balzer T
Invest Radiol; 2018 Sep; 53(9):541-550. PubMed ID: 29547493
[TBL] [Abstract][Full Text] [Related]
17. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.
Zou Z; Ma L
Indian J Dermatol; 2011 Jan; 56(1):65-73. PubMed ID: 21572796
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
